StockBeat: AstraZeneca’s Alexion Move Deserves a Better Reaction
By Geoffrey Smith Investing.com -- AstraZeneca (NASDAQ:AZN) has come up with a good, old-fashioned acquisition to remind everyone what biotech M&A used to be all about before the pandemic. The company has agreed to buy U.S.-based Alexion (NASDAQ:ALXN) for $39 billion, a move that will launch it into the high-margin world of treatments for rare diseases. In doing so, it will diversify its...
Continue reading